Aiosyn
Aiosyn uses artificial intelligence to improve the accuracy and consistency of pathology-based diagnostics for cancer and chronic kidney disease. The company develops AI-powered pathology algorithms and delivers them as modular medical software—available via cloud or on-premise deployments—that integrate with existing digital pathology platforms and laboratory workflows. Key technologies and products include an IVDR-certified mitotic figure counting solution for breast cancer grading, automated slide quality control, and the NephroPath platform for quantitative kidney biomarker analysis used in preclinical and clinical studies. Aiosyn primarily serves digital pathology labs, contract research organizations, and biopharma customers to support diagnostics and drug development.
Aiosyn
Aiosyn uses artificial intelligence to improve the accuracy and consistency of pathology-based diagnostics for cancer and chronic kidney disease. The company develops AI-powered pathology algorithms and delivers them as modular medical software—available via cloud or on-premise deployments—that integrate with existing digital pathology platforms and laboratory workflows. Key technologies and products include an IVDR-certified mitotic figure counting solution for breast cancer grading, automated slide quality control, and the NephroPath platform for quantitative kidney biomarker analysis used in preclinical and clinical studies. Aiosyn primarily serves digital pathology labs, contract research organizations, and biopharma customers to support diagnostics and drug development.